Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248074 | 1.00 | TRPV4 (0.46) | TRPV4NPSR1TRPV1MRGPRX4SLC6A3 | |
| SCHEMBL2538972 | 0.79 | GAA (0.46) | TRPV4NPSR1TRPV1KCNH2 | |
| SCHEMBL3760727 | 0.79 | GAA (0.46) | TRPV4NPSR1TRPV1KCNH2 | |
| SCHEMBL28558708 | 0.78 | TRPV4 (0.48) | TRPV4TRPV1MRGPRX4SLC6A3KCNH2 | |
| SCHEMBL627545 | 0.78 | TRPV4 (0.48) | TRPV4TRPV1MRGPRX4SLC6A3KCNH2 | |
| SCHEMBL30395883 | 0.78 | TRPV4 (0.48) | TRPV4TRPV1MRGPRX4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL5125109 | 0.76 | TRPV4 (0.47) | TRPV4TRPV1MRGPRX4SLC6A3KCNH2 | |
| Hydrochloric Acid SCHEMBL28549563 | 0.76 | TRPV4 (0.47) | TRPV4TRPV1MRGPRX4SLC6A3KCNH2 | |
| SCHEMBL22359307 | 0.76 | CYP2A6 (0.35) | NPSR1 | |
| SCHEMBL4396411 | 0.75 | NAPRT (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902227-B2 | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents | JANSSEN PHARMACEUTICA NV. (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902227-B2 | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents | JANSSEN PHARMACEUTICA NV. (BE) | 2011-03-08 | — | — | US | disclosed |
| US-7902227-B2 | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents | JANSSEN PHARMACEUTICA NV. (BE) | 2011-03-08 | — | — | US | disclosed |
| WO-2010093341-A1 | C-7 ISOXAZOLINYL QUINOLONE/NAPHTHYRIDINE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | WO | disclosed |
| US-20090029980-A1 | C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029980-A1 | C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
| US-20090029980-A1 | C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029980-A1 | C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents | CASP7, CYP3A7, NQO2 | TRPV4 3383/4885NPSR1 3808/4885TRPV1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.